Procalcitonin levels in relation to disease severity, specific treatment and diabetes comorbidity during pulmonary Tuberculosis.

MASSA ESTEFANIA; GALLUCCI GEORGINA; DIAZ ARIANA; FERNANDEZ ROCIO DEL VALLE; BÉRTOLA DIEGO; BOTTASSO OSCAR; DATTILIO, LUCIANO; BONGIOVANNI BETTINA; BAY MARÍA LUISA

CDMX

Congreso; The Latin American Society of Tuberculosis and other Mycobacteriosis (SLAM-TB) X virtual Meeting; 2021

Latin American Society of Tuberculosis and other Mycobacteriosis (SLAM-TB)

Tuberculosis (TB) patients show a neuro-immune-endocrine imbalance, consisting of elevated plasma levels of proinflammatory cytokines along with an increased cortisol/dehydroepiandrosterone ratio. Since procalcitonin (PCT) plasma levels are modulated by inflammatory cytokines, we evaluated this propeptide in TB patients. Blood samples from 35 newly diagnosed TB patients whose pulmonary disease was classified into mild, moderate, and severe (chest X-ray) were obtained. Subsequently, a cohort of pulmonary TB (n=20) was followed-up, with PCT being quantified at diagnosis (T0) and after two months (T2) of specific chemotherapy. Additionally, samples from TB patients with diabetes comorbidity (TB+DBT) were collected. PCT levels were assessed by an electrochemiluminescence immunoassay (Elecsys BRAHMS PCT, Roche) in a cobas e 411 analyzer (Roche, cut off value: 0.1 ng/ml. TB showed significantly higher levels of PCT with respect to age- and sex-matched Controls (Co, p=0.0003). When analyzing according to disease severity, severe TB cases presented the highest levels of PCT significantly different from the ones recorded in Co (p